-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tumor is a common disease.
With the aging of China's population and the influence of industrialization and urbanization, the incidence of tumor in China is increasing year by year, with an annual growth rate of 10%
.
With the continuous expansion of patients' needs, the tumor market has become a must for pharmaceutical companies.
Currently, both domestic and foreign companies are actively deploying in this field, increasing investment, and betting on occupying market share in this field
.
According to research data, the global tumor immunotherapy market space will reach 48 billion US dollars by 2022, while the Chinese tumor immunotherapy market will reach more than 12 billion US dollars by 2025
.
So, what trends will the tumor market have in the future? First, Chinese oncology drugs are still dominated by traditional chemical drugs, but from the perspective of the overall research and development trend, targeted drug therapy and immunotherapy are developing rapidly, and the industry expects that they will become an important force in the field of anti-tumor in the future
.
From the perspective of research and development, in recent years, both domestic and foreign pharmaceutical companies and scientific research centers have paid more attention to monoclonal antibody drugs and bispecific antibody drugs in targeted therapy, as well as CAR-T and immune detection in immunotherapy.
point inhibitor
.
Second, the Outline of the "Healthy China 2030" Plan puts forward a health concept focusing on prevention, and intends to provide cancer patients with more treatment options through various means, effectively improve drug availability, and reduce the burden of drug use for cancer patients.
in order to achieve a 15% improvement in the 5-year survival rate
.
In addition, the "Healthy China Action" also focuses on the two cores of disease prevention and health promotion.
The major special actions arranged and deployed include cancer prevention and control actions, especially for cancer prevention, early screening, early diagnosis and early treatment
.
It is foreseeable that in the future, China's coverage of cancer and other disease detection will increase, which also requires enterprises to develop more excellent and economical testing instruments and reagent consumables
.
Third, in recent years, the State Food and Drug Administration has accelerated the review and approval of new drugs, which is conducive to accelerating the research and development of cancer drugs, and industry supervision has become more stringent
.
In July 2021, CDE issued a notice on the public solicitation of opinions on the "Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented to Clinical Value".
guide"
.
These contents make it clear that anti-tumor drug research and development should reflect clinical value, and drug research and development companies need to change their thinking, focus on patient needs, and be guided by clinical value to solve unmet clinical needs
.
Fourth, for the approval of oncology drugs, evidence of efficacy from the real world is important
.
As defined by the FDA, real-world data (RWD) is data obtained from sources other than traditional clinical trials
.
These sources include large-scale simple clinical trials, clinical trials in actual medical care, prospective observational or registry studies, retrospective database analysis, case reports, health management reports, electronic health records,
etc.
The industry pointed out that the approval speed of domestic oncology drugs is relatively fast, but there are limitations in randomized clinical trials (RCTs)
.
In recent years, with the promotion of policies, a number of RWD companies have begun to emerge in China.
It is expected that the real-world data industry, as an emerging industry, has great potential in the future
.
With the aging of China's population and the influence of industrialization and urbanization, the incidence of tumor in China is increasing year by year, with an annual growth rate of 10%
.
With the continuous expansion of patients' needs, the tumor market has become a must for pharmaceutical companies.
Currently, both domestic and foreign companies are actively deploying in this field, increasing investment, and betting on occupying market share in this field
.
According to research data, the global tumor immunotherapy market space will reach 48 billion US dollars by 2022, while the Chinese tumor immunotherapy market will reach more than 12 billion US dollars by 2025
.
So, what trends will the tumor market have in the future? First, Chinese oncology drugs are still dominated by traditional chemical drugs, but from the perspective of the overall research and development trend, targeted drug therapy and immunotherapy are developing rapidly, and the industry expects that they will become an important force in the field of anti-tumor in the future
.
From the perspective of research and development, in recent years, both domestic and foreign pharmaceutical companies and scientific research centers have paid more attention to monoclonal antibody drugs and bispecific antibody drugs in targeted therapy, as well as CAR-T and immune detection in immunotherapy.
point inhibitor
.
Second, the Outline of the "Healthy China 2030" Plan puts forward a health concept focusing on prevention, and intends to provide cancer patients with more treatment options through various means, effectively improve drug availability, and reduce the burden of drug use for cancer patients.
in order to achieve a 15% improvement in the 5-year survival rate
.
In addition, the "Healthy China Action" also focuses on the two cores of disease prevention and health promotion.
The major special actions arranged and deployed include cancer prevention and control actions, especially for cancer prevention, early screening, early diagnosis and early treatment
.
It is foreseeable that in the future, China's coverage of cancer and other disease detection will increase, which also requires enterprises to develop more excellent and economical testing instruments and reagent consumables
.
Third, in recent years, the State Food and Drug Administration has accelerated the review and approval of new drugs, which is conducive to accelerating the research and development of cancer drugs, and industry supervision has become more stringent
.
In July 2021, CDE issued a notice on the public solicitation of opinions on the "Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented to Clinical Value".
guide"
.
These contents make it clear that anti-tumor drug research and development should reflect clinical value, and drug research and development companies need to change their thinking, focus on patient needs, and be guided by clinical value to solve unmet clinical needs
.
Fourth, for the approval of oncology drugs, evidence of efficacy from the real world is important
.
As defined by the FDA, real-world data (RWD) is data obtained from sources other than traditional clinical trials
.
These sources include large-scale simple clinical trials, clinical trials in actual medical care, prospective observational or registry studies, retrospective database analysis, case reports, health management reports, electronic health records,
etc.
The industry pointed out that the approval speed of domestic oncology drugs is relatively fast, but there are limitations in randomized clinical trials (RCTs)
.
In recent years, with the promotion of policies, a number of RWD companies have begun to emerge in China.
It is expected that the real-world data industry, as an emerging industry, has great potential in the future
.
